Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Chronix Biomedical is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 3 distinct examiners, which means that every pending action is being reviewed by a different individual. This high level of examiner diversity is mirrored in the administrative structure, as the portfolio is also spread across 3 distinct art units. Such a spread indicates that the company's intellectual property covers a variety of specific sub-sectors within the pharmaceutical field.
The busiest examiner for this portfolio is WILDER, CYNTHIA B, who is currently handling 1 pending office action. Given that there are 3 pending actions in total, this examiner's workload represents a portion of the active portfolio. Each of the 3 distinct examiners is responsible for exactly 1 pending action, creating a decentralized prosecution environment. The presence of 3 distinct art units suggests that the company must adapt its legal strategies to three different sets of examination norms. Practitioners should be aware that with 3 separate examiners and art units, there is no single point of contact.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILDER, CYNTHIA B | 1 | 71.0% | +26.6% |
| KAPUSHOC, STEPHEN THOMAS | 1 | 46.5% | +53.5% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +48.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17503056 | DETECTION AND QUANTIFICATION OF DONOR CELL-FREE DNA IN THE CIRCULATION OF ORGAN TRANSPLANT RECIPIENTS | KAPUSHOC, STEPHEN THOMAS | 107d overdue |
| 16284963 | PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | SITTON, JEHANNE SOUAYA | 44d overdue |
| 17914933 | METHODS FOR PRECISE AND BIAS-FREE QUANTIFICATION OF CELL-FREE DNA | WILDER, CYNTHIA B | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1683 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17914933 | METHODS FOR PRECISE AND BIAS-FREE QUANTIFICATION OF CELL-FREE DNA | WILDER, CYNTHIA B | 1681 | §102 | Final Rejection | — | Pending | Sep 27, 2022 |
| 17503056 | DETECTION AND QUANTIFICATION OF DONOR CELL-FREE DNA IN THE CIRCULATION OF ORGAN TRANSPLANT RECIPIENTS | KAPUSHOC, STEPHEN THOMAS | 1683 | §103§112DP | Final Rejection | 107d overdue | Pending | Oct 15, 2021 |
| 16284963 | PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | SITTON, JEHANNE SOUAYA | 1682 | §112DP | Non-Final OA | 44d overdue | Pending | Feb 25, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial